The comparison of the OS between the three groups of patients, i.e., (a) melanoma BRAF wild-type, (b) BRAF mutant (BRAFmut) treatment naïve and (c) pretreated with BRAF/MEKi (before ICI) melanoma showed a significantly better OS for patients in the first two groups (p = 0.01) (Figure S1b, Table S13). Here, BRAF is linked to melanoma.